Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Novocure's Phase 3 PANOVA-3 trial demonstrated that Tumor Treating Fields (TTFields) therapy, when combined with gemcitabine and nab-paclitaxel, resulted in a statistically significant improvement in overall survival (mOS of 16.2 months vs. 14.2 months, HR 0.82; p=0.039) for patients with unresectable, locally advanced pancreatic adenocarcinoma. The study also showed improvements in one-year survival rates (68.1% vs 60.2%, p=0.029) and pain-free survival (15.2 months vs 9.1 months, p=0.027), with Novocure planning to submit these data to the FDA in the second half of 2025 for premarket approval.

Analysis

Novocure's (NASDAQ: NVCR) Phase 3 PANOVA-3 trial has yielded statistically significant and clinically meaningful results, demonstrating that its Tumor Treating Fields (TTFields) therapy, when used concomitantly with gemcitabine and nab-paclitaxel, improves overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma. Specifically, patients receiving the TTFields combination therapy achieved a median OS of 16.2 months compared to 14.2 months for those on chemotherapy alone, a 2.0-month improvement (HR 0.82; p=0.039). This positions TTFields as the first treatment to show such an OS benefit in a Phase 3 trial for this challenging patient population. Supporting this primary endpoint, the trial also reported a statistically significant improvement in the one-year survival rate (68.1% vs. 60.2%; p=0.029) and a notable 6.1-month extension in median pain-free survival (15.2 months vs. 9.1 months; HR 0.74, p=0.027), a critical outcome given the severe pain associated with pancreatic cancer. Furthermore, quality of life metrics, including deterioration-free survival in global health status, pain, and digestive problems, were significantly improved. The therapy was well-tolerated, with no new safety signals observed. While these outcomes are highly positive, the trial did not show statistically significant differences in other secondary endpoints such as progression-free survival, local progression-free survival, or objective response rate. Novocure plans to submit these data to the FDA in the second half of 2025 to support a premarket approval application, signaling a potential shift in the standard of care for a disease with a dire prognosis, where only about 13% of patients survive five years post-diagnosis.

Key Decisions for Investors

• The positive Phase 3 PANOVA-3 results, particularly the statistically significant overall survival and pain-free survival benefits, represent a major clinical de-risking event for Novocure and could establish TTFields therapy as a new standard of care in unresectable, locally advanced pancreatic cancer, a market with high unmet need.
• Investors should closely monitor Novocure's planned FDA submission in the second half of 2025 and subsequent regulatory interactions, as successful approval would be a key valuation catalyst and unlock significant commercial opportunity.
• While the primary endpoint success is compelling, the lack of statistical significance in certain secondary endpoints like progression-free survival warrants consideration; attention should also be given to forthcoming data from the PANOVA-4 trial in metastatic pancreatic cancer, expected in the first half of 2026, for a broader view of TTFields' potential in pancreatic cancer.